Drug intelligence / Profile preview

HRS-9231

Development stage: Phase 3
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

HRS-9231 is a macrocyclic gadolinium-based contrast agent (GBCA) developed by Jiangsu Hengrui Pharmaceuticals for use in magnetic resonance imaging (MRI). It is designed to enhance lesion visualization in the central nervous system (CNS) and other body regions by shortening the T1 and T2 relaxation times of nearby water protons, thereby increasing signal intensity and improving image contrast. Clinical development has progressed to Phase III for body MRI and Phase II for CNS MRI, with studies comparing its efficacy and safety to gadobutrol. The agent is also being evaluated for its pharmacokinetic profile in subjects with renal impairment.

Other names: HRS-9231 InjectionHRS9231 InjectionHRS 9231 Injection

Beyond the preview

Go deeper on HRS-9231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-9231.

Explore the full profile